UNSPSC 51112003: Erlotinib

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C22H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4T82NDH7E, chemically known as 4-quinazolinamine, n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, but generally known as erlotinib, which bears US NIH Compound Identifier 176870. European Medicines Agency schedules Erlotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16423MIG.

UNSPSC 51112003 Erlotinib, a Commodity code, covers generic pharmaceutical products supplied through cooperative purchasing agreements to state and local government health systems and facilities. The recent activity under this code reflects broader pharmaceutical procurement frameworks where state and local agencies source named-drug products—in this case, erlotinib and other generics—through multi-vendor contracts that mandate compliance with Good Manufacturing Practices, Drug Supply Chain Security Act requirements, and FDA standards. State and local governments buying under this code typically operate through multistate cooperative purchasing alliances rather than standalone institutional procurement, which allows them to achieve volume pricing and simplified vendor management across participating jurisdictions. Issuing bodies include state departments of administration and health systems that participate in regional cooperative purchasing vehicles, often administering contracts on behalf of multiple member states and localities simultaneously.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The solicitation emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with administrative data formatting and EDI capability standards, and vendor relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Awarded vendors must maintain $5 million commercial general liability coverage, $2 million network security and privacy liability coverage, and $2 million professional liability coverage, with contract terms running two years for new vendors and extending through June 30, 2028 for incumbents. The contract becomes effective July 1, 2026, with vendors subject to performance penalties ranging from $200 to $1,500 per violation and required to remit a 3 percent administrative fee on all contract purchases.